Advertisement Daiichi, NGM enter into research collaboration - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Daiichi, NGM enter into research collaboration

Daiichi Sankyo and NGM Biopharmaceuticals have collaborated to discover and develop novel therapeutics that modulate beta-cell regeneration for the treatment of diabetes.

As per the agreement, NGM will apply its integrated discovery technology and in vivo screening platform to identify and validate physiologically-relevant metabolic targets that modulate beta-cell growth and function.

Daiichi and NGM will conduct research on selected targets to optimize drug candidates for further development.

Daiichi will be responsible for preclinical studies, clinical development, manufacturing and commercialization on a worldwide basis.

According to the agreement, Daiichi will receive a worldwide license to develop and commercialize compounds resulting from the collaboration.

NGM will receive an upfront payment, research funding and is even eligible to receive payments upon the achievement of research, development, regulatory and commercial milestones, as well as royalties on product sales.

Daiichi Sankyo R&D unit head Kazunori Hirokawa said the collaboration will expand the company’s research activities in the cardiovascular metabolic area.